ATE411016T1 - Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten - Google Patents
Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheitenInfo
- Publication number
- ATE411016T1 ATE411016T1 AT98940886T AT98940886T ATE411016T1 AT E411016 T1 ATE411016 T1 AT E411016T1 AT 98940886 T AT98940886 T AT 98940886T AT 98940886 T AT98940886 T AT 98940886T AT E411016 T1 ATE411016 T1 AT E411016T1
- Authority
- AT
- Austria
- Prior art keywords
- estrogen
- treatment
- prophylaxis
- dependent diseases
- dependent
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 230000001419 dependent effect Effects 0.000 abstract 2
- 229940011871 estrogen Drugs 0.000 abstract 2
- 239000000262 estrogen Substances 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5588197P | 1997-08-15 | 1997-08-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE411016T1 true ATE411016T1 (de) | 2008-10-15 |
Family
ID=22000784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98940886T ATE411016T1 (de) | 1997-08-15 | 1998-08-14 | Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten |
Country Status (21)
Country | Link |
---|---|
US (1) | US7307102B2 (de) |
EP (1) | EP1019057B1 (de) |
JP (1) | JP2001515038A (de) |
KR (1) | KR20010022956A (de) |
CN (1) | CN1275911A (de) |
AT (1) | ATE411016T1 (de) |
AU (1) | AU757206B2 (de) |
BR (1) | BR9811946A (de) |
CA (1) | CA2301032C (de) |
CZ (1) | CZ300929B6 (de) |
DE (1) | DE69840126D1 (de) |
EE (1) | EE200000077A (de) |
ES (1) | ES2312189T3 (de) |
HU (1) | HUP0002852A3 (de) |
IL (1) | IL134445A0 (de) |
NO (1) | NO20000752L (de) |
NZ (1) | NZ502738A (de) |
PL (1) | PL338555A1 (de) |
RU (1) | RU2214236C2 (de) |
UA (1) | UA70925C2 (de) |
WO (1) | WO1999008682A1 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6413533B1 (en) * | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
AU4676999A (en) | 1998-06-12 | 1999-12-30 | Ligand Pharmaceuticals, Inc. | Treatment of anti-estrogen resistant breast cancer using rxr modulators |
GB9824207D0 (en) * | 1998-11-04 | 1998-12-30 | Zeneca Ltd | Neurological disorders |
AU5957500A (en) * | 1999-07-06 | 2001-01-22 | Endorecherche Inc. | Methods of treating and/or suppressing weight gain |
CO5271709A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
US6417394B2 (en) * | 2000-04-05 | 2002-07-09 | Bristol Myers Squibb Pharma Company | Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators |
US6528681B2 (en) | 2000-04-05 | 2003-03-04 | Bristol-Meyers Squibb Pharma Company | Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
WO2002002006A1 (en) * | 2000-07-05 | 2002-01-10 | Seely Andrew J E | Method and apparatus for multiple patient parameter variability analysis and display |
ATE415161T1 (de) * | 2001-02-15 | 2008-12-15 | Janssen Pharmaceutica Nv | Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen |
US20020164581A1 (en) * | 2001-03-12 | 2002-11-07 | Chawnshang Chang | Methods for identifying compounds that do not attenuate the protective effects of estrogen |
WO2003016270A2 (en) | 2001-08-11 | 2003-02-27 | Bristol-Myers Squibb Pharma Company | Selective estrogen receptor modulators |
DK1768657T3 (da) | 2004-06-23 | 2008-12-01 | Sirion Therapeutics Inc | Fremgangsmåder og sammensætninger til at behandle ophthalmiske tilstande med retinylderivater |
AU2005304822B2 (en) | 2004-11-04 | 2008-10-16 | Sirion Therapeutics, Inc. | Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation |
SG144145A1 (en) * | 2004-12-08 | 2008-07-29 | Sirion Therapeutics Inc | Methods, assays and compositions for treating retinol-related diseases |
US20060264413A1 (en) * | 2005-04-18 | 2006-11-23 | Sri International | Method and composition for inhibiting cell proliferation and angiogenesis |
UA81382C2 (en) * | 2005-07-11 | 2007-12-25 | Composition for treating retinol-related diseases by modulation of retinol binding | |
JP2010540127A (ja) * | 2007-10-03 | 2010-12-24 | オタワ ヘルス リサーチ インスティチュート | 1つ以上の臓器の経時的生理的パラメータ変動を監視するための方法および装置 |
WO2009151683A2 (en) | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
AU2009313927A1 (en) | 2008-11-13 | 2010-05-20 | Astrazeneca Ab | Azaquinolinone derivatives and uses thereof |
MX2012014431A (es) | 2010-06-10 | 2013-02-26 | Aragon Pharmaceuticals Inc | Modulares del receptor de estrogenos y usos de los mismos. |
US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
CN102532073A (zh) * | 2011-12-30 | 2012-07-04 | 北京赛林泰医药技术有限公司 | 作为选择性***受体调节剂的乙烯衍生物 |
CN102584687A (zh) * | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 作为选择性***受体调节剂的乙烯衍生物 |
PE20142461A1 (es) | 2012-03-20 | 2015-02-05 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno y sus usos |
EP3386968A4 (de) * | 2015-12-09 | 2019-09-25 | The Board of Trustees of the University of Illinois | Benzothiophenbasierte selektive östrogenrezeptor-herunterregulierende präparate |
CA3071270A1 (en) * | 2017-07-28 | 2019-01-31 | Recurium Ip Holdings, Llc | Acrylic acid analogs |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637389A (de) | 1962-09-13 | |||
GB1029221A (en) | 1963-09-02 | 1966-05-11 | Ici Ltd | Triarylalkane derivatives |
GB1079747A (en) | 1965-07-07 | 1967-08-16 | Ici Ltd | Alkene derivatives |
US3637856A (en) | 1965-07-12 | 1972-01-25 | Ici Ltd | Trans-1-p-(dialkylaminoalkyl) phenyl-1 2-diphenyl-alk-1-enes and salts thereof |
GB1128379A (en) | 1966-06-20 | 1968-09-25 | Ici Ltd | Novel alkene derivatives, process for the preparation thereof and compositions containing the same |
GB1560274A (en) | 1977-02-28 | 1980-02-06 | Ici Ltd | Phenylbut 1-ene derivatives having antiostrogenicactivity |
US4206234A (en) | 1977-08-22 | 1980-06-03 | Imperial Chemical Industries Limited | Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof |
EP0002097B1 (de) | 1977-08-22 | 1981-08-05 | Imperial Chemical Industries Plc | Triphenylalken-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten |
EP0019377B1 (de) | 1979-05-15 | 1982-08-04 | Imperial Chemical Industries Plc | 1-Hydrocarbyloxyphenyl-1.2-diphenylalken-Derivate, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzung |
HU178253B (en) | 1979-08-15 | 1982-04-28 | Gyogyszerkutato Intezet | Process for preparing 1,1,2-triphenyl-propane and -propane derivatives |
DE3046719C2 (de) | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
FI77839C (fi) | 1982-05-27 | 1989-05-10 | Farmos Oy | Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat. |
US5491173A (en) * | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
CA1229604A (en) | 1984-02-14 | 1987-11-24 | Lorne J. Brandes | Aminoalkyl ethers of phenols as antiproliferative anticancer agents |
US4760053A (en) | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
US4729999A (en) | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
GB8604528D0 (en) | 1986-02-24 | 1986-04-03 | Ici Plc | Therapeutic agents |
US4859695A (en) | 1986-06-10 | 1989-08-22 | Merck & Co., Inc. | Antiestrogen agents having anabolic activity in animals |
CA1289570C (en) | 1986-06-16 | 1991-09-24 | Tetsuji Asao | 1,1,2-triaryl-1-alkene derivatives |
DE3736682A1 (de) | 1987-10-29 | 1989-05-11 | Klinge Co Chem Pharm Fab | Verfahren zur herstellung von trans-1,1,2-triphenyl-but-1-en-derivaten |
US5393785A (en) | 1988-10-31 | 1995-02-28 | Endorecherche, Inc. | Therapeutic antiestrogens |
US5119827A (en) | 1990-09-05 | 1992-06-09 | Board Of Regents, The University Of Texas System | Mechanisms of antiestrogen resistance in breast cancer |
US5189212A (en) * | 1990-09-07 | 1993-02-23 | University Of Georgia Research Foundation, Inc. | Triarylethylene carboxylic acids with estrogenic activity |
AU664161B2 (en) | 1990-10-01 | 1995-11-09 | Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives and uses thereof |
EP0589039A1 (de) | 1991-04-30 | 1994-03-30 | Asahi Kasei Kogyo Kabushiki Kaisha | Triphenylethylenderivate und sie enthaltende pharmazeutische präparation |
WO1994006762A1 (en) | 1992-09-15 | 1994-03-31 | Merrell Dow Pharmaceuticals Inc. | Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors |
DE4311870C2 (de) * | 1993-04-10 | 1998-07-30 | Altramed Holdings Ltd | Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US5455275A (en) * | 1994-05-11 | 1995-10-03 | Eli Lilly And Company | Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives |
-
1998
- 1998-08-14 CN CN98810214A patent/CN1275911A/zh active Pending
- 1998-08-14 IL IL13444598A patent/IL134445A0/xx not_active IP Right Cessation
- 1998-08-14 NZ NZ502738A patent/NZ502738A/en unknown
- 1998-08-14 CA CA002301032A patent/CA2301032C/en not_active Expired - Fee Related
- 1998-08-14 ES ES98940886T patent/ES2312189T3/es not_active Expired - Lifetime
- 1998-08-14 RU RU2000106448/14A patent/RU2214236C2/ru not_active IP Right Cessation
- 1998-08-14 WO PCT/US1998/016864 patent/WO1999008682A1/en not_active Application Discontinuation
- 1998-08-14 JP JP2000509421A patent/JP2001515038A/ja active Pending
- 1998-08-14 AT AT98940886T patent/ATE411016T1/de not_active IP Right Cessation
- 1998-08-14 KR KR1020007001564A patent/KR20010022956A/ko active Search and Examination
- 1998-08-14 DE DE69840126T patent/DE69840126D1/de not_active Expired - Fee Related
- 1998-08-14 PL PL98338555A patent/PL338555A1/xx unknown
- 1998-08-14 EE EEP200000077A patent/EE200000077A/xx unknown
- 1998-08-14 CZ CZ20000531A patent/CZ300929B6/cs not_active IP Right Cessation
- 1998-08-14 AU AU89063/98A patent/AU757206B2/en not_active Ceased
- 1998-08-14 HU HU0002852A patent/HUP0002852A3/hu unknown
- 1998-08-14 UA UA2000020847A patent/UA70925C2/uk unknown
- 1998-08-14 BR BR9811946-0A patent/BR9811946A/pt not_active IP Right Cessation
- 1998-08-14 EP EP98940886A patent/EP1019057B1/de not_active Expired - Lifetime
-
2000
- 2000-02-15 NO NO20000752A patent/NO20000752L/no not_active Application Discontinuation
-
2003
- 2003-03-18 US US10/390,032 patent/US7307102B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7307102B2 (en) | 2007-12-11 |
IL134445A0 (en) | 2001-04-30 |
DE69840126D1 (de) | 2008-11-27 |
AU757206B2 (en) | 2003-02-06 |
HUP0002852A3 (en) | 2001-11-28 |
WO1999008682A1 (en) | 1999-02-25 |
CZ300929B6 (cs) | 2009-09-16 |
EP1019057B1 (de) | 2008-10-15 |
CZ2000531A3 (en) | 2001-05-16 |
AU8906398A (en) | 1999-03-08 |
KR20010022956A (ko) | 2001-03-26 |
US20030232795A1 (en) | 2003-12-18 |
EP1019057A4 (de) | 2006-06-14 |
NO20000752D0 (no) | 2000-02-15 |
EE200000077A (et) | 2000-12-15 |
NZ502738A (en) | 2002-06-28 |
EP1019057A1 (de) | 2000-07-19 |
BR9811946A (pt) | 2000-08-22 |
HUP0002852A2 (hu) | 2001-10-28 |
UA70925C2 (uk) | 2004-11-15 |
RU2214236C2 (ru) | 2003-10-20 |
CA2301032A1 (en) | 1999-02-25 |
CA2301032C (en) | 2009-01-13 |
CN1275911A (zh) | 2000-12-06 |
NO20000752L (no) | 2000-02-15 |
PL338555A1 (en) | 2000-11-06 |
JP2001515038A (ja) | 2001-09-18 |
ES2312189T3 (es) | 2009-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE411016T1 (de) | Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten | |
DE69826695D1 (de) | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen | |
ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
DE69931377D1 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
ATE300292T1 (de) | Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren | |
ATE258796T1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
ATE415962T1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
ATE198706T1 (de) | Polyamin-verbindungen zur behandlung von proliferativer erkrankungen | |
ATE362374T1 (de) | Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust | |
GB9815177D0 (en) | Treatment of skin disorders | |
ATE271873T1 (de) | Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz | |
ATE222119T1 (de) | Verwendung von erythropoietin zur behandlung von multiple myelom | |
DE60237039D1 (de) | Verfahren zur behandlung von rosacea und telangiectasia | |
ATE239467T1 (de) | Methode zur behandlung oder verhütung von interstitieller blasenentzundung | |
ATE251462T1 (de) | Verfahren zur behandlung von narbengewebe | |
DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
ATE206052T1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
ATE360425T1 (de) | Verwendung von quetiapin für die behandlung von kokain-abhängigkeit | |
ATE369143T1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
ATE291434T1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
DE69919578D1 (de) | VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten | |
ATE291431T1 (de) | Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |